Significant whole genes are distributed throughout the genome and sex-based phenotypes. by Adam N. Spierer (10325544)

Fig 1 - by Seraphine Zeitouny (16954499)

Subjects:

Total and resource-specific absolute costs (in 2020 CAD) per quarter in 2020 and percentage change from 2018 and 2019 for all individuals in Ontario. by Seraphine Zeitouny (16954499)

Subjects:

Characteristics of the individuals in the first week of 2020 in Ontario and British Columbia. by Seraphine Zeitouny (16954499)

Subjects:

Fig 2 - by Seraphine Zeitouny (16954499)

Subjects:

Total and resource-specific absolute costs per quarter in 2020 (in 2020 CAD) and percentage change from 2018 and 2019 for all individuals in British Columbia. by Seraphine Zeitouny (16954499)

Subjects:

Total healthcare costs per 10,000 person-weeks (in 2020 CAD) in each ISO week from January 1, 2018 to December 27, 2020 in Ontario and British Columbia (BC). by Seraphine Zeitouny (16954499)

Subjects:

Independent variants with a meta-analysis genome-wide significant association with Horvath-based or Hannum-based epigenetic age acceleration. by Jude Gibson (2954124)

“…<p>Independent variants with a meta-analysis genome-wide significant association with Horvath-based or Hannum-based epigenetic age acceleration.…”

Significant relationships between QOL measures on infusion day and day 7. by Jordan K. Abbott (8934239)

Subjects:

Distribution of <i>L</i>(<i>p</i>) with an absolute error when a single observation is randomly sampled at each time point, with the smallest observation (blue) and the largest obs... by Hyeontae Jo (20469463)

Subjects:

The distribution of <i>Giardia duodenalis</i> assemblages in domestic and wild populations of nonhuman mammalian species with a larger number of isolates. by Kareem Hatam-Nahavandi (7384790)

Subjects:

Phase 2 significant effects. by Wendy C. Crone (2262169)

Phase 1 significant effects. by Wendy C. Crone (2262169)

Sensitivity analyses of seroprevalence with the largest sample size study omitted. by Yu Zhou (89766)

Change in Watt’s Connectedness Scale, Subscales by Treatment Group. by Benjamin R. Lewis (22279166)

Subjects:

Primary and secondary efficacy end points (intention-to-treat population). by Benjamin R. Lewis (22279166)

Subjects:

Demographic and clinical characteristics of participants at baseline. by Benjamin R. Lewis (22279166)

Subjects:

Study-related adverse events. by Benjamin R. Lewis (22279166)

Subjects:

Study flow chart. by Benjamin R. Lewis (22279166)

Subjects:

Change in QIDS-SR-16 and MBI-HSS-MP by Treatment Group. by Benjamin R. Lewis (22279166)

Subjects: